Doris Radun

Doris Radun

Auto-generated profile, based on publicly available information

Doris Radun

Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2008 in BMC Public Health
Verified
Journal Article
Open access
PDF file
KSKarl Schenkel
Karl Schenkel
DRDoris Radun
Doris Radun
VBViviane Bremer
Viviane Bremer
NBNikolaus Bocter
Nikolaus Bocter
OHOsamah Hamouda
Osamah Hamouda
In Germany, vaccination against hepatitis B is recommended for infants, children and adolescents since 1995 and for specific target groups since 1982. Little is known about knowledge about viral hepatitis and attitudes toward hepatitis B vaccination-factors likely to influence vaccine uptake.

1 January 2011 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
WCWei Cai
Wei Cai
CPChristina Poethko-Müller
Christina Poethko-Müller
OHOsamah Hamouda
Osamah Hamouda
DRDoris Md Radun
Doris Md Radun
Background: Data on hepatitis B (HB) infection prevalence among children and adolescents in Germany are scarce. We estimated seroprevalence of HB infection and assessed determinants for HB infection among children and adolescents in Germany from a representative population sample. Methods: From 2003 to 2006, the Robert Koch Institute conducted a nationwide cross-sectional Health Interview and Examination Survey for Children and Adolescents in Germany. Data on age, gender, migration background, and socioeconomic status were collected through questionnaires. A child was defined as having a 2-sided migration background if both parents, or the child and 1 parent, immigrated, and a 1-sided migration background if only 1 parent immigrated. Among children with migration background, a first-generation migrant was defined as born outside Germany; a second-generation migrant was born in Germany. Information on HB vaccination status was obtained from vaccination cards. Serologic samples from participants were tested for anti-hepatitis B core antigen (anti-HBc) and hepatitis B surface antigen. We performed weighted univariable and multivariable logistic regression analyses to assess determinants for HB infection. Results: Of 13,065 participants (3–17 years), 0.5% (95% confidence interval [CI], 0.4–0.7) were anti-HBc positive, among whom 38.7% (95% CI, 20.0–57.5) were hepatitis B surface antigen positive. Two-sided migration background and being a first- or second-generation migrant were significantly associated with anti-HBc positivity (odds ratio [OR]: 8.3, 95% CI: 4.0–17.4; OR: 11.0, 95% CI: 3.5–35.0; OR: 3.0, 95% CI: 1.2–7.3). No further determinants were found. Conclusions: HB infection is rare among children and adolescents in Germany. First- and second-generation migrant children can be considered to be at risk for HB infection, 2-sided migration background or being a first-generation migrant carried the greatest risk. Targeted testing for HB infection and early HB vaccination should be provided to immigrants' children.

14 January 2010 in Eurosurveillance
Verified
Journal Article
Open access
DRD Radun
D Radun
HBH Bernard
H Bernard
MAM Altmann
M Altmann
ISI Schöneberg
I Schöneberg
VBV Bochat
V Bochat
GKG Krause
G Krause
A fatal case of anthrax occurred in an injecting drug user in Germany, in December 2009. A potential link to similar cases in Scotland in the same time period is currently under investigation.

17 March 2010 in Epidemiology and Infection
Verified
Journal Article
Closed access
PDF file
PJP. Jorgensen
P. Jorgensen
CPC. Poethko-Müller
C. Poethko-Müller
WHW. Hellenbrand
W. Hellenbrand
WJW. Jilg
W. Jilg
WTW. Thierfelder
W. Thierfelder
DRD. Radun
D. Radun
SUMMARY: The success of childhood vaccination against hepatitis B relies on persistence of immunity into adolescence and adulthood. In 2000, two hexavalent vaccines with a hepatitis B component (Hexavac®, Infanrix hexa®) were introduced in Germany. Hexavac was withdrawn in 2005 amidst concerns about its long-term hepatitis B protection. We compared hepatitis B surface antibody (anti-HBs) levels in children fully vaccinated with Hexavac or Infanrix hexa (n=477) in a secondary data analysis of a large cross-sectional health survey in Germany. On average 2·4 years after vaccination, 25·3% of Hexavac vaccinees had anti-HBs levels <10 mIU/ml (95% CI 19·0–32·8) compared to 4·7% of Infanrix hexa vaccinees (95% CI 2·4–8·9). These findings suggest that short-term hepatitis B immunogenicity in Hexavac vaccinees may also be weaker. Further studies are warranted to assess whether Hexavac vaccinees should be re-vaccinated or receive a booster vaccination before these birth cohorts reach adolescence.